SCHEMBL4255032

SCHEMBL4255032

Cn1c(=O)c2c(c3ccccc31)OC(N)=C(C#N)C2c1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.59
TP53 P04637 2/20 0.59
TSHR P16473 2/20 0.54
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
LMNA P02545 5/20 0.50
POLB P06746 3/20 0.50
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 5/20 0.49
HTT P42858 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 4/20 0.44
TDP1 Q9NUW8 2/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
HIF1A Q16665 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 1/20 0.43
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254591 0.89 TP53 (0.54) MAPTTP53TSHRKMT2AMEN1
SCHEMBL4259180 0.88 MAPT (0.49) MAPTTP53KMT2AMEN1LMNA
SCHEMBL4253512 0.88 MAPT (0.66) MAPTTP53TSHRKMT2AMEN1
SCHEMBL4256965 0.88 MAPT (0.51) MAPTTP53TSHRKMT2AMEN1
SCHEMBL4259370 0.86 KDM4E (0.50) MAPTTP53TSHRKMT2AMEN1
SCHEMBL4256343 0.85 MYB (0.61) MAPTTP53TSHRKMT2AMEN1
SCHEMBL4255338 0.84 SMN1; SMN2 (0.47) MAPTTP53TSHRKMT2AMEN1
SCHEMBL4252395 0.84 MAPT (0.48) MAPTTP53KMT2AMEN1LMNA
SCHEMBL4249301 0.83 MAPT (0.63) MAPTTSHRKMT2AMEN1LMNA
SCHEMBL4256225 0.82 KDM4E (0.61) MAPTTP53TSHRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349864-B2 Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) 2013-01-08 US disclosed
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof BAX, CASP3, CASP7 MAPT 3099/4885TP53 54/4885TSHR 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.